• 1. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526
• 2. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090
• 3. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 4. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 5. Evidence of field induced slow magnetic relaxation in cis-[Co(hfac)2(H2O)2] exhibiting tri-axial anisotropy with a negative axial component?
  Denis V. Korchagin,Elena A. Yureva,Alexander V. Akimov,Eugenii Ya. Misochko,Gennady V. Shilov,Artem D. Talantsev,Roman B. Morgunov,Alexander A. Shakin,Sergey M. Aldoshin,Boris S. Tsukerblat Dalton Trans., 2017,46, 7540-7548

Introduction to 3-5-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-ylpropanenitrile (CAS No. 1006334-26-4)

3-5-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-ylpropanenitrile is a sophisticated organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal biology. This compound, identified by its CAS number 1006334-26-4, represents a unique structural motif characterized by the integration of a pyrazole ring, a phenyl group, and a trifluoromethyl-substituted propanenitrile moiety. Such structural features not only contribute to its distinct chemical properties but also open up diverse possibilities for its application in drug discovery and development.

The pyrazole core is a heterocyclic aromatic compound that is widely recognized for its versatility in medicinal chemistry. Pyrazoles exhibit a broad spectrum of biological activities, including anti-inflammatory, antimicrobial, and anticancer properties. The presence of a phenyl group in 3-5-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-ylpropanenitrile further enhances its pharmacological potential by introducing additional aromaticity and electronic effects. This combination of structural elements makes the compound an attractive candidate for further exploration in the development of novel therapeutic agents.

The trifluoromethyl group is another critical feature of this compound, known for its ability to modulate metabolic stability, lipophilicity, and binding affinity. In drug design, trifluoromethyl groups are frequently incorporated to improve the pharmacokinetic properties of molecules. The nitrile functionality in the propanenitrile chain adds another layer of complexity, potentially influencing both the reactivity and biological activity of the compound. Together, these structural components contribute to a rich chemical space that warrants detailed investigation.

Recent advancements in computational chemistry and molecular modeling have enabled researchers to predict the biological activity of compounds like 3-5-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-ylpropanenitrile with greater accuracy. These tools have been instrumental in identifying potential binding interactions with biological targets, such as enzymes and receptors. For instance, studies have suggested that the pyrazole ring may interact with heme-containing proteins, while the phenyl group could engage in π-stacking interactions with aromatic residues in proteins. Such insights are crucial for designing molecules with optimized bioactivity.

In vitro studies have begun to unravel the pharmacological profile of 3-5-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-ylpropanenitrile. Preliminary experiments indicate that this compound exhibits promising activity against certain cancer cell lines, likely due to its ability to disrupt key signaling pathways involved in tumor growth and progression. Additionally, the trifluoromethyl group may enhance its binding affinity to target proteins, making it a potent inhibitor in vitro. These findings align with broader trends in oncology research, where structurally diverse molecules are being explored to overcome resistance mechanisms associated with existing therapies.

The integration of machine learning algorithms has further accelerated the discovery process for compounds like 3-5-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-ylpropanenitrile. By leveraging large datasets of known bioactive molecules, these algorithms can predict new scaffolds that may exhibit similar or enhanced biological activities. This approach has already led to the identification of novel drug candidates that would have been challenging to discover through traditional experimental methods alone. The combination of computational screening with experimental validation represents a powerful strategy for accelerating drug development pipelines.

Future directions for research on 3-5-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-ylpropanenitrile include exploring its potential as an intermediate in synthetic chemistry and evaluating its efficacy in preclinical models. The compound’s unique structural features make it an excellent starting point for generating derivatives with tailored biological properties. By systematically modifying specific functional groups, researchers can optimize its potency, selectivity, and pharmacokinetic profile for therapeutic applications.

The broader significance of this compound lies in its contribution to the expanding library of heterocyclic derivatives being investigated for medicinal use. Pyrazoles and their derivatives continue to be among the most studied classes of compounds due to their diverse biological activities and synthetic accessibility. As research progresses, compounds like 3-(trifluoromethyl)-substituted pyrazole nitriles are likely to play an increasingly important role in addressing unmet medical needs across various therapeutic areas.

In conclusion,3-(trifluoromethyl)-substituted pyrazol-propanenitriles, exemplified by CAS No 1006334264, represent a promising class of pharmaceutical intermediates with significant potential for drug discovery. Their unique structural features—comprising a pyrazole ring, trifluoromethyl substitution, phenyl moiety, and nitrile group—make them versatile candidates for further exploration. Advances in computational chemistry, machine learning, and high-throughput screening are expected to accelerate the development pipeline for such compounds, ultimately leading to novel therapeutic agents that address critical unmet medical needs.

• 123066-64-8(CRAC intermediate 2)
• 154471-65-5(1-Methyl-3-(trifluoromethyl)-1H-pyrazole)
• 362601-71-6(3-[4-(Trifluoromethyl)phenyl]-1H-pyrazole)
• 198348-94-6(1-Acetyl-5-phenyl-3-(trifluoromethyl)-1H-pyrazole)
• 4203-77-4(Vat Red 13)
• 169590-42-5(Celecoxib)
• 36140-83-7(3-(3,5-dimethylpyrazol-1-yl)-3-oxo-propanenitrile)
• 49866-87-7(Difenzoquat)
• 93323-67-2(Pyrazole-1-acetic Acid, 3,5-diphenyl-)
• 17629-26-4(1-Ethyl-4-iodo-3,5-dimethyl-1H-pyrazole)